Shares of Exelixis, Inc. (NASDAQ:EXEL) ended Thursday session in green amid volatile trading. The shares closed up +0.52 points or 3.81% at $14.16 with 6.11 million shares getting traded. Post opening the session at $13.08, the shares hit an intraday low of $13.07 and an intraday high of $14.28 and the price vacillated in this range throughout the day. The company has a market cap of $3.28 billion and the numbers of outstanding shares have been calculated to be 230.33 million shares.
Exelixis, Inc. (EXEL) provided an update on the timing of a key data presentation for cabozantinib at the European Society for Medical Oncology (ESMO) 2016 Congress, which is being held October 7-11, 2016 in Copenhagen, Denmark. Detailed results from CABOSUN, the randomized phase 2 clinical trial of cabozantinib compared with sunitinib in patients with previously untreated advanced renal cell carcinoma (RCC), has been selected for the Presidential Symposium 3 session on Monday, October 10, 2016, starting at 16:30 CEST (local Copenhagen time) / 10:30 a.m. EDT / 7:30 a.m. PDT.
Shares of Medivation Inc (NASDAQ:MDVN) ended Thursday session at $80.90 with 3.71 million shares getting traded. Post opening the session at $80.94, the shares hit an intraday low of $80.86 and an intraday high of $81.04 and the price vacillated in this range throughout the day. The company has a market cap of $13.43 billion and the numbers of outstanding shares have been calculated to be 165.93 million shares.
Medivation Inc (MDVN) on August 09, 2016 reported its financial results for the quarter ended June 30, 2016 and reaffirmed full-year 2016 financial guidance.
U.S. net sales of XTANDI® (enzalutamide) capsules, as recorded by Astellas, were $330.3 million for the quarter ended June 30, 2016, an increase of $31.8 million (+11% compared to the second quarter of 2015). The year-over-year net sales growth was driven by an 18% increase in underlying demand, partially offset by a lower net selling price resulting from a higher gross-to-net rate. Ex-U.S. net sales of XTANDI, as recorded by Astellas, were approximately $265 million for the quarter, an increase of $76 million (+41% compared to the second quarter of 2015).
“For the second consecutive quarter, XTANDI was the leading novel hormonal agent in the U.S. We continue to see increases in duration of therapy and new patient starts as well as accelerating uptake in the urology market,” said David Hung, M.D., Founder, President and Chief Executive Officer of Medivation. “In addition, we anticipate a very exciting second half of 2016 for XTANDI as we prepare commercially for the October 22 PDUFA date for a potential U.S. label amendment to include head-to-head data of enzalutamide versus bicalutamide. We also expect top-line results from our Phase II ER/PR positive breast cancer trial and our PLATO trial before year end. Looking ahead into next year, we anticipate the completion of enrollment for PROSPER, our Phase III trial in non-metastatic castration-resistant prostate cancer, as well as potentially top-line results from this study.”